1.  Home
  2. Whitepapers
  3. Vascular-Targeted Phototherapy Study for Prostate Cancer

Vascular-Targeted Phototherapy Study for Prostate Cancer

Download Whitepaper

Vascular-Targeted Phototherapy Study for Prostate Cancer

Download Whitepaper
Vascular-targeted phototherapy (VTP) was developed by Avigdor Scherz (Weizmann Institute of Science), and it is now owned by Steba Biotech. VTP agent Tookad was clinically approved for low-risk prostate cancer in Europe, Mexico, and Israel after successful multi-center Phase 3 trials. Phase 2 trial has been recently conducted at MSK for intermediate risk prostate cancer by Dr. Jonathan Coleman. VTP is also being investigated for other indications, such as for upper tract urothelial carcinoma in an ongoing Phase 1 trial at MSK.

Download Whitepaper Now